DISHMAN CARBOGEN AMCIS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 229.6 INR | -1.61% |
|
+3.89% | +34.34% |
| Apr. 01 | Dishman Carbogen Amcis Limited Announces Board Cessations | CI |
| Mar. 19 | Dishman Carbogen Amcis Arm Gets GMP Certificate from Brazilian Authority for Shanghai Site | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Companyâs segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q4 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +34.34% | 432M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DCAL Stock
- News Dishman Carbogen Amcis Limited
- Dishman Carbogen Amcis Arm Gets GMP Certificate from Brazilian Authority for Shanghai Site
